Quick Take
Anchiano Therapeutics (ANCN) intends to raise $35 million in a U.S. IPO, per an amended regulatory filing.
The company is developing a single biologic candidate to treat bladder and other cancers.
ANCN has had promising trial results, strong existing investor support of the IPO, and a low IPO valuation, but the early stage of its development may mean the IPO is more appropriate for high risk, long-term life science investors.
Company & Technology
Israel-based Anchiano was founded in 2004 to develop treatments for patients with bladder cancer, pancreatic cancer, and